FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898858914> ?p ?o ?g. }

• W2898858914 endingPage "694" @default.
• W2898858914 startingPage "694" @default.
• W2898858914 abstract "Treatment of Raynaud phenomenon (RP) with phosphodiesterase-5 inhibitors has shown moderate efficacy. Adverse effects decrease the risk-benefit profile of these drugs, and patients may not be willing to receive long-term treatment. On-demand single doses before or during exposure to cold may be a good alternative.To assess the efficacy and safety of on-demand sildenafil in RP.Series of randomized, double-blind, n-of-1 trials. (ClinicalTrials.gov: NCT02050360).Outpatients at a French university hospital.Patients with primary or secondary RP.Each trial consisted of a multiple crossover study in a single patient. Repeated blocks of 3 periods of on-demand treatment were evaluated: 1 week of placebo, 1 week of sildenafil at 40 mg per dose, and 1 week of sildenafil at 80 mg per dose, with a maximum of 2 doses daily.Raynaud Condition Score (RCS) and frequency and daily duration of attacks. Skin blood flow in response to cooling also was assessed with laser speckle contrast imaging. Mixed-effects models were used and parameters were estimated in a Bayesian framework to determine individual and aggregated efficacy.38 patients completed 2 to 5 treatment blocks. On the basis of aggregated data, the probability that sildenafil at 40 mg or 80 mg was more effective than placebo was greater than 90% for all outcomes (except for RCS with sildenafil, 80 mg). However, the aggregated effect size was not clinically relevant. Yet, substantial heterogeneity in sildenafil's efficacy was observed among participants, with clinically relevant efficacy in some patients.The response to sildenafil was substantially heterogeneous among patients.Despite a high probability that sildenafil is superior to placebo, substantial heterogeneity was observed in patient response and aggregated results did not show that on-demand sildenafil has clinically relevant efficacy. In this context, the use of n-of-1 trials may be an original and relevant approach in RP.GIRCI (Groupement Interrégional de Recherche Clinique et d'Innovation) Auvergne Rhône-Alpes (academic funding) and Pfizer." @default.
• W2898858914 created "2018-11-09" @default.
• W2898858914 creator A5005052958 @default.
• W2898858914 creator A5008130520 @default.
• W2898858914 creator A5014929711 @default.
• W2898858914 creator A5019544924 @default.
• W2898858914 creator A5023154269 @default.
• W2898858914 creator A5025534708 @default.
• W2898858914 creator A5027910872 @default.
• W2898858914 creator A5054708539 @default.
• W2898858914 creator A5065252955 @default.
• W2898858914 creator A5067957384 @default.
• W2898858914 creator A5074659805 @default.
• W2898858914 creator A5075149767 @default.
• W2898858914 creator A5085374876 @default.
• W2898858914 creator A5087118108 @default.
• W2898858914 date "2018-10-30" @default.
• W2898858914 modified "2023-10-16" @default.
• W2898858914 title "On-Demand Sildenafil as a Treatment for Raynaud Phenomenon" @default.
• W2898858914 cites W1595121224 @default.
• W2898858914 cites W2005553418 @default.
• W2898858914 cites W2013178875 @default.
• W2898858914 cites W2021559411 @default.
• W2898858914 cites W2040159339 @default.
• W2898858914 cites W2041064238 @default.
• W2898858914 cites W2042225280 @default.
• W2898858914 cites W2054504088 @default.
• W2898858914 cites W2093492017 @default.
• W2898858914 cites W2096107056 @default.
• W2898858914 cites W2110511303 @default.
• W2898858914 cites W2113654265 @default.
• W2898858914 cites W2124159683 @default.
• W2898858914 cites W2129990616 @default.
• W2898858914 cites W2133197025 @default.
• W2898858914 cites W2152215868 @default.
• W2898858914 cites W2342819438 @default.
• W2898858914 cites W2386513494 @default.
• W2898858914 cites W2469201213 @default.
• W2898858914 cites W2475141720 @default.
• W2898858914 cites W2549071917 @default.
• W2898858914 cites W2751882620 @default.
• W2898858914 cites W2774833117 @default.
• W2898858914 cites W4205594235 @default.
• W2898858914 cites W4239306672 @default.
• W2898858914 doi "https://doi.org/10.7326/m18-0517" @default.
• W2898858914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30383134" @default.
• W2898858914 hasPublicationYear "2018" @default.
• W2898858914 type Work @default.
• W2898858914 sameAs 2898858914 @default.
• W2898858914 citedByCount "24" @default.
• W2898858914 countsByYear W28988589142019 @default.
• W2898858914 countsByYear W28988589142020 @default.
• W2898858914 countsByYear W28988589142021 @default.
• W2898858914 countsByYear W28988589142022 @default.
• W2898858914 countsByYear W28988589142023 @default.
• W2898858914 crossrefType "journal-article" @default.
• W2898858914 hasAuthorship W2898858914A5005052958 @default.
• W2898858914 hasAuthorship W2898858914A5008130520 @default.
• W2898858914 hasAuthorship W2898858914A5014929711 @default.
• W2898858914 hasAuthorship W2898858914A5019544924 @default.
• W2898858914 hasAuthorship W2898858914A5023154269 @default.
• W2898858914 hasAuthorship W2898858914A5025534708 @default.
• W2898858914 hasAuthorship W2898858914A5027910872 @default.
• W2898858914 hasAuthorship W2898858914A5054708539 @default.
• W2898858914 hasAuthorship W2898858914A5065252955 @default.
• W2898858914 hasAuthorship W2898858914A5067957384 @default.
• W2898858914 hasAuthorship W2898858914A5074659805 @default.
• W2898858914 hasAuthorship W2898858914A5075149767 @default.
• W2898858914 hasAuthorship W2898858914A5085374876 @default.
• W2898858914 hasAuthorship W2898858914A5087118108 @default.
• W2898858914 hasConcept C126322002 @default.
• W2898858914 hasConcept C142724271 @default.
• W2898858914 hasConcept C168563851 @default.
• W2898858914 hasConcept C197934379 @default.
• W2898858914 hasConcept C204787440 @default.
• W2898858914 hasConcept C27081682 @default.
• W2898858914 hasConcept C2776768464 @default.
• W2898858914 hasConcept C42219234 @default.
• W2898858914 hasConcept C71924100 @default.
• W2898858914 hasConcept C74534348 @default.
• W2898858914 hasConcept C87813604 @default.
• W2898858914 hasConceptScore W2898858914C126322002 @default.
• W2898858914 hasConceptScore W2898858914C142724271 @default.
• W2898858914 hasConceptScore W2898858914C168563851 @default.
• W2898858914 hasConceptScore W2898858914C197934379 @default.
• W2898858914 hasConceptScore W2898858914C204787440 @default.
• W2898858914 hasConceptScore W2898858914C27081682 @default.
• W2898858914 hasConceptScore W2898858914C2776768464 @default.
• W2898858914 hasConceptScore W2898858914C42219234 @default.
• W2898858914 hasConceptScore W2898858914C71924100 @default.
• W2898858914 hasConceptScore W2898858914C74534348 @default.
• W2898858914 hasConceptScore W2898858914C87813604 @default.
• W2898858914 hasFunder F4320324320 @default.
• W2898858914 hasIssue "10" @default.
• W2898858914 hasLocation W28988589141 @default.
• W2898858914 hasLocation W28988589142 @default.
• W2898858914 hasLocation W28988589143 @default.
• W2898858914 hasLocation W28988589144 @default.

• next